Iron Home > Curriculum > Curriculum 5 > Iron Overload and Its Management in Non-Transfusion-Dependent Thalassaemia
Iron Overload and Its Management in Non-Transfusion-Dependent Thalassaemia
The non-transfusion-dependent thalassaemias are a group of thalassaemias that include beta thalassaemia intermedia, haemoglobin E beta thalassaemia, and haemoglobin H disease. These diseases vary dramatically in clinical presentation, from individuals who are non-transfusion-dependent and asymptomatic until adult life to those with much more severe disease who require transfusion. Despite the wide spectrum of these disorders, iron overload and iron-related complications can occur in all of these patients, including those who do not receive transfusions. Join Dr. Ali Taher for Iron Overload and Its Management in Non-Transfusion-Dependent Thalassaemia (NTDT), as he discusses the causes and complications of iron overload in non-transfusion-dependent thalassaemias and need for iron monitoring and chelation therapy in patients with these complex diseases.
Target AudienceThis activity is designed for haematologists, medical oncologists, haematology-oncology specialists, and other healthcare professionals involved in the screening, evaluation, treatment, and management of adults and children with iron overload, resulting from the spectrum of chronic iron overload diseases.
- Assess risk factors for iron overload in patients with nonâtransfusion-dependent thalassaemia to identify patients requiring iron chelation therapy to reduce iron overload and associated complications
- Evaluate the efficacy and safety of iron chelation therapy in reducing iron overload and risk of iron-related complications in patients with nonâtransfusion-dependent thalassaemia
- Compare methods for measuring total body iron in patients with nontransfusion-dependent thalassaemia to ensure use of the most accurate measures of body iron in these patients
||Ali T. Taher, MD
Department of Internal Medicine
American University of Beirut Medical Center
|Ali T. Taher, MD
is on the speakers bureau of and on the advisory board for Novartis Pharmaceuticals Corporation.
The Curriculum in Iron Metabolism & Related Disorders is supported by an educational grant from
1 avenue Claude Vellefaux.
75475 Paris Cedex 10, France
All Rights Reserved
Copyright ESH 2020